Belite Bio reported an initial statement of beneficial ownership for director Gary Clark Biddle. The filing listed stock options to buy 50,000 ordinary shares at USD 6 per share. It also listed stock options to buy 60,000 ordinary shares at USD 58.88 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-113608), on March 18, 2026, and is solely responsible for the information contained therein.
Comments